What Annex 1 is
EU GMP Annex 1 is the European guideline on the manufacture of sterile medicinal products. The 2022 revision — which came into operation in August 2023 — introduced significant new requirements including a mandatory Contamination Control Strategy (CCS) and updated expectations for environmental monitoring, cleanroom behaviour and aseptic manufacturing.
For cannabis operators, the direct relevance depends on product type. Operators manufacturing sterile cannabis medicines — injectable preparations, sterile eye drops — are fully within scope. But even operators producing non-sterile cannabis products find Annex 1 relevant in a specific and important way.
Scope for cannabis manufacturing
Many cannabis extracts and oral preparations are manufactured in Grade C or Grade D environments — controlled but not sterile. Annex 1 does not apply to these areas in the same way it applies to Grade A and Grade B sterile environments. However, the 2022 Annex 1 introduced concepts that regulators now expect to see applied more broadly.
The Contamination Control Strategy is the most important of these. Annex 1 now requires manufacturers to demonstrate they have a holistic, documented approach to contamination risk — not just environmental monitoring data, but a systematic strategy addressing contamination sources, control measures, monitoring, investigation and improvement.
Contamination Control Strategy
A CCS is a documented, risk-based approach to identifying contamination risks and demonstrating they are effectively controlled. For cannabis operators, it should address microbial contamination from raw plant material, particulate contamination during processing, cross-contamination between products or batches, and personnel-related contamination.
Inspectors visiting cannabis facilities in Germany, the Netherlands and Portugal are increasingly asking to see CCS documentation. Facilities without a CCS — even those not manufacturing sterile products — are receiving observations during audits.
Cleanroom grades for cannabis environments
EU GMP defines four cleanroom grades: A (critical zone for aseptic operations), B (background for Grade A), C (manufacture of products requiring a controlled environment) and D (less critical manufacturing stages). Most non-sterile cannabis manufacturing occurs in Grade C or D environments, with Grade A isolators used where critical open-product handling occurs.
Understanding which grade applies to each production zone — and maintaining environmental monitoring, gowning, cleaning and equipment qualification appropriate to that grade — is a core GMP competency for any cannabis manufacturing team.
References
- EU GMP Annex 1 (2022) — Manufacture of Sterile Medicinal Products
- PIC/S Recommendation on the Validation of Aseptic Processes (PI 007-6)
- ISO 14644-1:2015 — Classification of Air Cleanliness by Particle Concentration
Confirm the current effective version and national applicability before operational, regulatory or clinical use.
Related content
Cleanrooms pillarCCGP CertificationCCVP CertificationCCS Template